首页> 美国卫生研究院文献>International Journal of Molecular Sciences >A Safe and Multitasking Antimicrobial Decapeptide: The Road from De Novo Design to Structural and Functional Characterization
【2h】

A Safe and Multitasking Antimicrobial Decapeptide: The Road from De Novo Design to Structural and Functional Characterization

机译:一种安全和多任务抗菌屑的抑制肽:从De Novo设计到结构和功能表征的道路

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antimicrobial peptides (AMPs) are excellent candidates to fight multi-resistant pathogens worldwide and are considered promising bio-preservatives to control microbial spoilage through food processing. To date, designing de novo AMPs with high therapeutic indexes, low-cost synthesis, high resistance, and bioavailability, remains a challenge. In this study, a novel decapeptide, named RiLK1, was rationally designed starting from the sequence of the previously characterized AMP 1018-K6, with the aim of developing short peptides, and promoting higher selectivity over mammalian cells, antibacterial activity, and structural resistance under different salt, pH, and temperature conditions. Interestingly, RiLK1 displayed a broad-spectrum of bactericidal activity against Gram-positive and Gram-negative bacteria, including multidrug resistant clinical isolates of Salmonella species, with Minimal Bactericidal Concentration (MBC) values in low micromolar range, and it was effective even against two fungal pathogens with no evidence of cytotoxicity on human keratinocytes and fibroblasts. Moreover, RiLK1-activated polypropylene films were revealed to efficiently prevent the growth of microbial spoilage, possibly improving the shelf life of fresh food products. These results suggested that de novo designed peptide RiLK1 could be the first candidate for the development of a promising class of decameric and multitask antimicrobial agents to overcome drug-resistance phenomena.
机译:抗微生物肽(AMPS)是在全世界对抗多种耐药病原体的优异候选者,并且被认为是通过食品加工控制微生物腐败的有前途的生物防腐剂。迄今为止,设计具有高治疗指标,低成本合成,高阻和生物利用度的De Novo AMPS仍然是一个挑战。在本研究中,从先前特征的AMP 1018-K6的序列开始,从先前特征的AMP 1018-K6的序列开始理性设计一种新的蒸馏孔,其目的是开发短肽,并促进对哺乳动物细胞的更高选择性,抗菌活性和结构抵抗力不同的盐,pH和温度条件。有趣的是,Rilk1展示了针对革兰氏阳性和革兰氏阴性细菌的广谱杀菌活性,包括沙门氏菌种类的多药抗性临床分离物,具有低微摩尔范围内的杀菌浓度(MBC)值,并且即使对两个有效真菌病原体没有人类角质形成细胞和成纤维细胞细胞毒性的证据。此外,揭示了Rilk1-活化的聚丙烯薄膜,以有效地防止微生物腐败的生长,可能改善新鲜食品的保质期。这些结果表明,De Novo设计的肽Rilk1可以是开发有前途的透明度和多任务抗菌药物的第一种候选者,以克服抗药性现象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号